亚洲日韩激情无码一区,中文字幕乱码无码人妻系列蜜桃,国产精品国产三级国产a,男女做爰猛烈啪啪吃奶,无码人妻av免费一区二区三区

On April 29th, the "Hangzhou Biomedicine Industry-Finance Summit," hosted by Tailong Investment and co-supported by Hangzhou Industrial Investment Group, High-tech Financial Investment Group, and Tigermed, was held in Binjiang District, Hangzhou. Quarkmed was invited to participate in this grand event, working hand in hand with all parties to promote the prosperous development of the biomedicine industry.

Vice Director Sheng Xiaorong of Hangzhou Investment Promotion Bureau, Gao Chong (Standing Committee Member of the Party Committee, Deputy Director of the Administrative Committee, and Deputy District Chief of Hangzhou High-tech Zone), Pan Xiaohui (Chairman of Hangzhou Industrial Investment Group), Wang Fengbin (Chairman of High-tech Financial Investment Group), Gao Fu (Academician of Chinese Academy of Sciences, Vice President of Chinese Medical Association), Dong Chen (Academician of Chinese Academy of Sciences, Academic Consultant of Chinese Academy of Medical Sciences, Vice President and Dean of School of Medicine at Westlake University), Xu Huji (Director of Internal Medicine and Rheumatology Department at Changzheng Hospital Affiliated to Naval Medical University), Ye Xiaoping (Chairman of Tigermed) and other distinguished guests attended the event. Participants engaged in in-depth discussions on cutting-edge biopharmaceutical technologies, industry development trends, and investment & financing strategies, exploring new opportunities for industry development.

At the summit's opening ceremony, Gao Chong stated in his speech that the High-tech Zone will continuously improve industrial and promote the clustering of innovative resources to create a better development environment for biopharmaceutical enterprises; Pan Xiaohui pointed out that Hangzhou Industrial Investment will give full play to its capital guidance role, accelerate the deep integration of industry and capital, and empower the innovative development of the biopharmaceutical industry.

Subsequently, Liu Chunguang, Managing Partner of Tailong Investment Management, provided a detailed introduction to Taikun Fund's investment layout and achievements in the biopharmaceutical field. To date, Taikun Fund has directly invested in over 90 life and health industry projects, and as an LP has invested in more than 50 high-quality GPs, driving coverage of over 400 high-quality projects and forming a strong industrial synergy effect. In terms of regional development in Hangzhou, Taikun Fund and its invested GPs have invested in more than 120 enterprises in Hangzhou, with a total investment amount exceeding 4 billion yuan. They have helped 9 directly invested enterprises grow into "unicorns" or "pre-unicorns" with valuations exceeding 1 billion yuan, and more than 10 enterprises have been awarded "specialized, refined, distinctive and innovative" qualifications, significantly enhancing Hangzhou's biopharmaceutical industry competitiveness and injecting strong momentum into regional industrial cluster construction.

At the unveiling ceremony of the highly anticipated "Hangzhou CRO Industrial Park", Wang Fengbin, Chairman of High-tech Financial Investment Group, and Ye Xiaoping, Chairman of Tigermed, jointly unveiled the park. Pan Xiaohui, Chairman of Hangzhou Industrial Investment Group, Sheng Xiaorong, Deputy Director of the Municipal Investment Promotion Bureau, and Gao Chong, Standing Committee Member of Hangzhou High-tech Zone (Binjiang) District Party Committee, Deputy Director of the Administrative Committee, and Deputy District Mayor, attended the ceremony as witnesses. As a crucial support force in biopharmaceutical research and development, the establishment of this park marks a new stage for Hangzhou in the field of biopharmaceutical R&D outsourcing services. It will further promote the clustering development of CRO industry in the region, attract more high-quality resources, and enhance Hangzhou's overall R&D capabilities and international competitiveness in the biopharmaceutical industry.

This summit specially set up an exhibition area for enterprises outside the main venue, with over 30 companies participating. Through physical displays and technical explanations, the participating companies presented the latest products, technological achievements, and innovative solutions in the biomedicine field, providing attendees with a platform to understand the cutting-edge industry trends and creating favorable conditions for exchanges and cooperation among enterprises.

This summit has injected new momentum into Hangzhou's biomedical industry innovation and development by deeply integrating resources from industry, academia, research, and capital, effectively promoting industrial upgrading and deep integration of capital and industry. Looking ahead, Tailong Investment will base itself on Hangzhou's industrial development needs, fully leverage its advantages in capital operation and industrial empowerment, and continuously increase investment layout and resource input in Hangzhou's biomedical field. By deepening cooperation with government, research institutions, and enterprises, we will further explore and cultivate local innovative enterprises, assist Hangzhou in building a more competitive biomedical industry cluster, continuously contribute to building an international first-class life and health industry highland, and propel Hangzhou's biomedical industry towards high-quality development.
Source: Tailong Investment